1
|
Fasola CE, Graham E, Sha W, Schepel CR, Trufan SJ, Hecksher A, White RL, Hadzikadic-Gusic L. Assessment of Postmastectomy Radiation Therapy Receipt by Age and Association With Outcomes in Women With Breast Cancer. Clin Breast Cancer 2024:S1526-8209(24)00057-0. [PMID: 38492996 DOI: 10.1016/j.clbc.2024.02.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 02/20/2024] [Accepted: 02/24/2024] [Indexed: 03/18/2024]
Abstract
PURPOSE Postmastectomy radiation therapy (PMRT) reduces locoregional recurrence (LRR) and improves overall survival (OS) in patients with breast cancer. Young age has been recognized as a risk factor for LRR. The primary objective of this study was to determine if recommendations for PMRT differed among patients younger than 50 years as compared to women aged 50 years or older. METHODS We reviewed medical records of patients with breast cancer who underwent mastectomy with or without PMRT from 2010 through 2018. Univariable and multivariable models were used to estimate the association of age with PMRT. RESULTS Of 2471 patients, 839 (34%) were <50 years; 1632 (66%) were ≥50 years. Patients <50 years had a higher percentage of grade 3 tumors, hormone receptor (HR) negative and/or Her-2/neu positive tumors, clinical stage T2/T3 tumors, and nodal involvement. Compared with patients ≥50 years, patients <50 years were more likely to undergo PMRT (OR 1.57; P = .001) and regional node irradiation (RNI) to the internal mammary nodes. Advanced clinical and pathologic stage, invasive tumor histology, the presence of lymphovascular invasion, and treatment with systemic chemotherapy were predictors of PMRT receipt for patients <50 years (P < .05). PMRT was associated with improved OS and recurrence free survival (RFS) among all patients (P < .01). CONCLUSION Patients <50 years were more likely to undergo PMRT and to receive RNI to the internal mammary nodes but were also more likely to have other risk factors for recurrence that would warrant a PMRT recommendation. PMRT improved OS and RFS for all patients.
Collapse
Affiliation(s)
- Carolina E Fasola
- Department of Radiation Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC
| | - Elaina Graham
- Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC
| | - Wei Sha
- Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC
| | - Courtney R Schepel
- Clinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC
| | - Sally J Trufan
- Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC
| | - Anna Hecksher
- Clinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC
| | - Richard L White
- Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC
| | - Lejla Hadzikadic-Gusic
- Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC.
| |
Collapse
|
2
|
Fasola CE, Sharp HJ, Clavin NW, Sha W, Schepel CR, Trufan SJ, Graham E, Hecksher A, White RL, Hadzikadic-Gusic L. ASO Visual Abstract: Effect of Delayed Oncoplastic Reduction Mammoplasty on Radiation Treatment Delay Following Breast-Conserving Surgery for Breast Cancer. Ann Surg Oncol 2024; 31:390. [PMID: 37755571 DOI: 10.1245/s10434-023-14310-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/28/2023]
Affiliation(s)
- Carolina E Fasola
- Department of Radiation Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Hadley J Sharp
- Department of Radiation Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Nick W Clavin
- Division of Plastic and Reconstructive Surgery, Atrium Health, Charlotte, NC, USA
| | - Wei Sha
- Department of Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Courtney R Schepel
- Clinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Sally J Trufan
- Department of Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Elaina Graham
- Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Anna Hecksher
- Clinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Richard L White
- Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Lejla Hadzikadic-Gusic
- Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
| |
Collapse
|
3
|
Fasola CE, Sharp HJ, Clavin NW, Sha W, Schepel CR, Trufan SJ, Graham E, Hecksher A, White RL, Hadzikadic-Gusic L. Effect of Delayed Oncoplastic Reduction Mammoplasty on Radiation Treatment Delay Following Breast-Conserving Surgery for Breast Cancer. Ann Surg Oncol 2023; 30:8362-8370. [PMID: 37605081 DOI: 10.1245/s10434-023-14177-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Accepted: 07/30/2023] [Indexed: 08/23/2023]
Abstract
BACKGROUND The purpose of this study was to evaluate the delay in initiating adjuvant radiation therapy (RT) after breast-conserving surgery (BCS) in patients with early-stage breast cancer who underwent oncoplastic reduction mammoplasty (ORM) following BCS compared with a matched cohort of patients who did not undergo ORM between BCS and RT. METHODS Medical records of 112 women (56 ORMs and 56 matched non-ORMs) with carcinoma in situ or early-stage breast cancer treated with BCS were reviewed. ORM was performed in a delayed manner following BCS, allowing confirmation of negative surgical margins. Time to RT was defined as time from last oncologic surgery to start of RT. RESULTS The median follow-up time was 6.8 years for the ORM cohort and 6.7 years for the control non-ORM cohort. Patients who underwent ORM following BCS experienced a significant delay in initiating RT (>8 weeks) than matched patients not undergoing ORM (66% vs. 34%; p < 0.001). Wound complications occurred in 44.6% (n = 25) of patients in the ORM cohort, which were mostly minor, including delayed wound healing and/or infection (39%). There was no significant difference in local recurrence between patients in the non-ORM and ORM cohorts (p = 0.32). CONCLUSIONS This study demonstrates that ORM following BCS has the potential to delay RT >8 weeks, largely as a result of increased risk of wound complications; however, this delay did not impact local control. ORM can be safely considered for appropriately selected patients with breast cancer.
Collapse
Affiliation(s)
- Carolina E Fasola
- Department of Radiation Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Hadley J Sharp
- Department of Radiation Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Nicholas W Clavin
- Division of Plastic and Reconstructive Surgery, Atrium Health, Charlotte, NC, USA
| | - Wei Sha
- Department of Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Courtney R Schepel
- Clinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Sally J Trufan
- Department of Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Elaina Graham
- Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Anna Hecksher
- Clinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Richard L White
- Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Lejla Hadzikadic-Gusic
- Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
| |
Collapse
|
4
|
White RL, Wallander ML, Leighliter ME, Sha W, Palmer PP, Sejdic A, Benbow JH, Sarma D, Robinson MM, Trufan SJ, Sarantou T. Assessing trends in breast care surveillance metrics after implementing surgeon-specific tracking and performance reporting in a large, integrated cancer network. Cancer 2023; 129:3230-3238. [PMID: 37382238 DOI: 10.1002/cncr.34924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Revised: 04/06/2023] [Accepted: 05/02/2023] [Indexed: 06/30/2023]
Abstract
BACKGROUND There are few quality metrics and benchmarks specific to surgical oncology. Development of a surgeon-level performance metrics system based on peer comparisons is hypothesized to positively influence surgical decision-making. This study established a tracking and reporting system comprised of evidence and consensus-based metrics to assess breast care delivered by individual surgeons. METHODS Surgeons' performance is assessed by a surveillance tracking system of metrics pertaining to referrals and surgical elements. This retrospective analysis of prospectively collected breast care data reports on recurring 6-month and cumulative data from nine care locations from 2015 to 2021. RESULTS Breast care was provided to 6659 patients by 41 surgeons. A total of 27 breast care metrics were evaluated over 7 years. Metrics with consistent, proficient results were retired after 18 months, including the rate of core biopsy, specimen orientation, and referrals to medical oncology, genetics, and fertility, among others. In clinically node-negative, hormone receptor-positive patients 70 years of age or older, the cumulative rate of sentinel lymph node (SLN) biopsy significantly decreased by 40% over 5.5 years (p < .001). The overall breast conservation rate for T0-T2 cancer increased 10% over 7 years. At the surgeon level, improvements were made in the median number of SLNs removed and in operative note documentation. CONCLUSIONS Implementation of a surgeon-specific, peer comparison-based metric and tracking system has yielded substantive changes in breast care management. This process and governance structure can serve as a model for quantification of breast care at other institutions and for other disease sites.
Collapse
Affiliation(s)
- Richard L White
- Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Michelle L Wallander
- Clinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Marjorie E Leighliter
- Breast Clinic, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Wei Sha
- Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Pooja P Palmer
- Division of Community and Social Impact, Atrium Health, Charlotte, North Carolina, USA
| | - Almira Sejdic
- Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Jennifer H Benbow
- Clinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Deba Sarma
- Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Myra M Robinson
- Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Sally J Trufan
- Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Terry Sarantou
- Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| |
Collapse
|
5
|
Squires MH, Donahue EE, Wallander ML, Trufan SJ, Shea RE, Lindholm NF, Hill JS, Salo JC. Factors Associated with Early Discharge after Non-Emergent Right Colectomy for Colon Cancer: A NSQIP Analysis. Curr Oncol 2023; 30:2482-2492. [PMID: 36826150 PMCID: PMC9954992 DOI: 10.3390/curroncol30020189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2023] [Revised: 02/08/2023] [Accepted: 02/14/2023] [Indexed: 02/22/2023] Open
Abstract
The National Surgical Quality Improvement Project (NSQIP) dataset was used to identify perioperative variables associated with the length of stay (LOS) and early discharge among cancer patients undergoing colectomy. Patients who underwent non-emergent right colectomy for colon cancer from 2012 to 2019 were identified from the NSQIP and colectomy-targeted databases. Postoperative LOS was analyzed based on postoperative day (POD) of discharge, with patients grouped into Early Discharge (POD 0-2), Standard Discharge (POD 3-5), or Late Discharge (POD ≥ 6) cohorts. Multivariable ordinal logistic regression was performed to identify risk factors associated with early discharge. The NSQIP query yielded 26,072 patients: 3684 (14%) in the Early Discharge, 13,414 (52%) in the Standard Discharge, and 8974 (34%) in the Late Discharge cohorts. The median LOS was 4.0 days (IQR: 3.0-7.0). Thirty-day readmission rates were 7% for Early Discharge, 8% for Standard Discharge, and 12% for Late Discharge. On multivariable regression analysis, risk factors significantly associated with a shorter LOS included independent functional status, minimally invasive approach, and absence of ostomy or additional bowel resection (all p < 0.001). Perioperative variables can be used to develop a model to identify patients eligible for early discharge after right colectomy for colon cancer. Efforts to decrease the overall median length of stay should focus on optimization of modifiable risk factors.
Collapse
Affiliation(s)
- Malcolm H. Squires
- Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USA
- Correspondence:
| | - Erin E. Donahue
- Department of Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USA
| | - Michelle L. Wallander
- Clinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USA
| | - Sally J. Trufan
- Department of Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USA
| | - Reilly E. Shea
- Clinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USA
| | - Nicole F. Lindholm
- Department of Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USA
| | - Joshua S. Hill
- Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USA
| | - Jonathan C. Salo
- Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USA
| |
Collapse
|
6
|
Frenkel CH, Brickman DS, Trufan SJ, Ward MC, Moeller BJ, Carrizosa DR, Sumrall AL, Milas ZL. Defining targets to improve care delivery for T4 larynx squamous cell carcinoma. Laryngoscope Investig Otolaryngol 2022; 7:1849-1856. [PMID: 36544914 PMCID: PMC9764812 DOI: 10.1002/lio2.959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Revised: 10/05/2022] [Accepted: 10/15/2022] [Indexed: 11/18/2022] Open
Abstract
Objective United States oncology trends consistently demonstrate that nearly half of T4a larynx carcinoma patients are treated with larynx preservation, despite national guidelines favoring laryngectomy. This study identifies clinical decision-making drivers and defines patient subsets that should become targets for care improvement. Methods Retrospective analysis of patients with cT4 squamous cell carcinoma of the larynx from US National Cancer Database 2005-2016. Demographic data and survival rates between clinical pathways were compared. Survival was estimated by Kaplan-Meier method with statistical comparisons assessed by log-rank test. Results Of 11,556 patients with cT4 disease, laryngectomy (TL) was the initial treatment for 4627 (40%) patients. Larynx preservation via chemoradiation (CRT) occurred for 4307 patients. TL and CRT patients had similar Charlson-Deyo comorbidity indices and insurance status. TL patients had higher total tumor size, lower N3 rates and were more often seen at academic institutions (p < .0001). N0 surgery patients with adjuvant treatment demonstrated superior median survival (MS) compared to CRT (surgery + radiation MS: 69 months, surgery + chemoradiation MS: 66, CRT MS: 37.7), p < .0001. MS for N1/N2 disease patients was 56.5 months for surgery + radiation and 35.5 months for surgery + CRT, superior to CRT, MS 30.8 months, p < .0001. Tri-modality N3 patients with up front surgery had similar MS compared to CRT (surgery + chemoradiation 21.3 months vs. CRT 16.1), p = .95. Conclusion National quality improvement initiatives are needed to promote guideline adherence and improve survival in advanced larynx cancer. Targets for such initiatives should be patients with limited or no nodal disease burden, that meet clear T4a imaging criteria. Level of Evidence Level IV, non-randomized controlled cohort.
Collapse
Affiliation(s)
- Catherine H. Frenkel
- Division of Head and Neck Surgical Oncology, Department of SurgeryLevine Cancer Institute, Atrium HealthCharlotteNorth CarolinaUSA
| | - Daniel S. Brickman
- Division of Head and Neck Surgical Oncology, Department of SurgeryLevine Cancer Institute, Atrium HealthCharlotteNorth CarolinaUSA
| | - Sally J. Trufan
- Department of BiostatisticsLevine Cancer Institute, Atrium HealthCharlotteNorth CarolinaUSA
| | - Matthew C. Ward
- Department of Radiation OncologyLevine Cancer Institute, Atrium HealthCharlotteNorth CarolinaUSA
| | - Benjamin J. Moeller
- Department of Radiation OncologyLevine Cancer Institute, Atrium HealthCharlotteNorth CarolinaUSA
| | - Daniel R. Carrizosa
- Department of Medical OncologyLevine Cancer Institute, Atrium HealthCharlotteNorth CarolinaUSA
| | - Ashley L. Sumrall
- Department of Medical OncologyLevine Cancer Institute, Atrium HealthCharlotteNorth CarolinaUSA
| | - Zvonimir L. Milas
- Division of Head and Neck Surgical Oncology, Department of SurgeryLevine Cancer Institute, Atrium HealthCharlotteNorth CarolinaUSA
| |
Collapse
|
7
|
Lavery L, DiSogra K, Lea J, Trufan SJ, Symanowski JT, Roberts A, Moore DC, Heeke A, Pal S. Risk factors associated with palbociclib-induced neutropenia in patients with metastatic breast cancer. Support Care Cancer 2022; 30:9803-9809. [PMID: 36260177 DOI: 10.1007/s00520-022-07400-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Accepted: 10/07/2022] [Indexed: 10/24/2022]
Abstract
BACKGROUND Neutropenia is the most common adverse event with palbociclib, an oral cyclin-dependent kinase 4/6 inhibitor, with grade 3/4 neutropenia occurring in up to 67% of patients in phase III trials evaluating this agent in metastatic breast cancer. This retrospective chart review assessed characteristics of patients on palbociclib to evaluate for risk factors in the development of grade 3/4 neutropenia. PATIENTS AND METHODS Patients with metastatic breast cancer who received palbociclib were included. Patient demographics collected included age, gender, race, body mass index, breast cancer treatment history, palbociclib starting dose, baseline absolute neutrophil count, baseline platelet count, concomitant hormonal therapy, concomitant use of denosumab, and use of concomitant strong CYP3A4 inhibitors/inducers. Events of interest occurring within 30 days of initiation of palbociclib were also noted including antibiotic and corticosteroid use, mucosal conditions, open wounds, or surgery. The incidence and potential risk factors for grade 3/4 neutropenia in the first 6 months of treatment were analyzed. RESULTS A total of 257 patients were included in the analysis with 206 patients (80.2%) and 139 patients (54.1%) experiencing all-grade neutropenia and grade 3/4 neutropenia, respectively. Multivariate analysis found baseline myelosuppression and recent antibiotic use to be independent predictors of grade 3/4 neutropenia. Normal weight patients had an increased risk for grade 3/4 neutropenia compared to obese patients by multivariate analysis. CONCLUSION The results of this study showed baseline myelosuppression and recent antibiotic use within 30 days of palbociclib initiation were predictive of a higher incidence of grade 3/4 neutropenia. Obese patients were less likely to develop grade 3/4 neutropenia compared to normal weight patients.
Collapse
Affiliation(s)
- Lesli Lavery
- Department of Pharmacy, Levine Cancer Institute, Atrium Health, 10660 Park Rd, Charlotte, NC, 28210, USA.
| | - Kristyn DiSogra
- Specialty Pharmacy Service, Atrium Health, 4400 Golf Acres Drive, Charlotte, NC, 28208, USA
| | - Julia Lea
- Department of Pharmacy, Levine Cancer Institute, 1021 Morehead Medical Drive, Charlotte, NC, 28204, USA
| | - Sally J Trufan
- Department of Biostatistics, Levine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, Charlotte, NC, 28204, USA
| | - James T Symanowski
- Department of Biostatistics, Levine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, Charlotte, NC, 28204, USA
| | - Ashley Roberts
- Specialty Pharmacy Service, Atrium Health, 4400 Golf Acres Drive, Charlotte, NC, 28208, USA
| | - Donald C Moore
- Department of Pharmacy, Levine Cancer Institute, 100 Medical Park Drive, Concord, NC, 28025, USA
| | - Arielle Heeke
- Department of Solid Tumor Oncology, Levine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, Charlotte, NC, 28204, USA
| | - Sridhar Pal
- Department of Solid Tumor Oncology, Levine Cancer Institute, Atrium Health, 10660 Park Rd, Charlotte, NC, 28210, USA
| |
Collapse
|
8
|
Hudson L, Reese E, Hecksher A, Schepel C, Trufan SJ, Cruz A, Verbyla A, White RL, Hadzikadic‐Gusic L. Cover Image, Volume 126, Number 2, August 1, 2022. J Surg Oncol 2022. [DOI: 10.1002/jso.27019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Laura Hudson
- Division of Surgical Oncology, Department of Surgery Levine Cancer Institute, Carolinas Medical Center Charlotte North Carolina USA
| | - Emily Reese
- EMD Serono Research and Development Institute, Inc Boston Massachusetts USA
| | - Anna Hecksher
- Division of Surgical Oncology, Department of Surgery Levine Cancer Institute, Carolinas Medical Center Charlotte North Carolina USA
| | - Courtney Schepel
- Division of Surgical Oncology, Department of Surgery Levine Cancer Institute, Carolinas Medical Center Charlotte North Carolina USA
| | - Sally J. Trufan
- Department of Cancer Biostatistics Levine Cancer Institute Charlotte North Carolina USA
| | - Adilen Cruz
- Department of Cancer Biostatistics, Health Economics and Outcomes Research Levine Cancer Institute Charlotte North Carolina USA
| | - Allison Verbyla
- Department of Cancer Biostatistics, Health Economics and Outcomes Research Levine Cancer Institute Charlotte North Carolina USA
| | - Richard L. White
- Division of Surgical Oncology, Department of Surgery Levine Cancer Institute, Carolinas Medical Center Charlotte North Carolina USA
| | - Lejla Hadzikadic‐Gusic
- Division of Surgical Oncology, Department of Surgery Levine Cancer Institute, Carolinas Medical Center Charlotte North Carolina USA
| |
Collapse
|
9
|
Hudson L, Reese E, Hecksher A, Schepel C, Trufan SJ, Cruz A, Verbyla A, White RL, Hadzikadic-Gusic L. Single surgeon versus co-surgeon bilateral mastectomy: Comparing outcomes and costs based on health economic modeling from the perspective of the hospital system. J Surg Oncol 2022; 126:239-246. [PMID: 35411951 DOI: 10.1002/jso.26891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 03/14/2022] [Accepted: 04/02/2022] [Indexed: 11/06/2022]
Abstract
INTRODUCTION Co-surgeon approach for bilateral mastectomy may lead to shorter operative times and improved outcomes compared with single-surgeon approach, but cost differences remain unclear. Economic models were applied to determine whether either approach offered a lower cost opportunity. METHODS A retrospective review of 409 patients undergoing single-surgeon or co-surgeon bilateral mastectomy between January 1, 2010 through April 30, 2016 was conducted. Outcomes included narcotic and antinausea doses, length of stay (LOS), and operative time. Analyses stratified by reconstruction and no reconstruction included Wilcoxon tests, Poisson regression, generalized linear models, and a cost calculator. RESULTS Of 409 patients, 310 had reconstruction and 99 had no reconstruction. Compared with single-surgeon approach, co-surgeon approach was associated with less operative time and shorter LOS (233 vs. 250 min and 1.0 vs. 1.8 days no reconstruction; and 429 vs. 493 min and 2.2 vs. 2.8 days reconstruction). Economic analysis demonstrated less operative time, shorter LOS, and lower average cost for co-surgeon approach ($32,400 vs. $34,400 no reconstruction; and $76,700 vs. $79,400 reconstruction). CONCLUSION Compared with the single-surgeon, the co-surgeon approach with reconstruction was associated with a statistically significant decrease in operative time and LOS. Economic analysis estimated the co-surgeon approach could lead to lower costs.
Collapse
Affiliation(s)
- Laura Hudson
- Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina, USA
| | - Emily Reese
- EMD Serono Research and Development Institute, Inc, Boston, Massachusetts, USA
| | - Anna Hecksher
- Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina, USA
| | - Courtney Schepel
- Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina, USA
| | - Sally J Trufan
- Department of Cancer Biostatistics, Levine Cancer Institute, Charlotte, North Carolina, USA
| | - Adilen Cruz
- Department of Cancer Biostatistics, Health Economics and Outcomes Research, Levine Cancer Institute, Charlotte, North Carolina, USA
| | - Allison Verbyla
- Department of Cancer Biostatistics, Health Economics and Outcomes Research, Levine Cancer Institute, Charlotte, North Carolina, USA
| | - Richard L White
- Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina, USA
| | - Lejla Hadzikadic-Gusic
- Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina, USA
| |
Collapse
|
10
|
Grigg C, Trufan SJ, Riggs SB, Clark PE, Matulay JT, Kearns JT, Zhu J, Raghavan D, Burgess EF. Survival of young black males with metastatic clear cell renal cell carcinoma. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.6_suppl.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
294 Background: Black men have the highest incidence of clear cell renal cell carcinoma (ccRCC) and have a worse prognosis than women or White patients in the curative setting. We previously reported that women with metastatic ccRCC have an inferior prognosis to men which is dynamic with age. The prognosis of Black patients with metastatic ccRCC is not well described. Methods: Clinicopathologic features and survival of patients diagnosed with clinical stage IV ccRCC between 2004-2016 were obtained from the National Cancer Database (NCDB). Patients were stratified according to their age at diagnosis, race, and sex. Uni- and multi-variable chi-square, logistic regression, and overall survival (OS) analyses were used for comparisons. Results: In this cohort, there were 900 Black men, 461 Black women, 13,422 White men, and 6363 White women. Black patients were less likely to have private insurance, lung metastases, or to live in high income zip codes and were more likely to have liver metastases. Compared to White race, Black race was associated with worse OS in the overall cohort (HR 1.17 [95% CI 1.10-1.24], p<0.001; multivariate HR 1.14 [95% CI 1.06-1.21], p<0.001) and in a smaller cohort limited to patients receiving systemic therapy as their initial treatment modality (n=10,869; HR 1.22 [95% CI 1.11-1.33], p<0.001). Within age groups, the highest disparity was observed among younger patients (<50yr: median OS 12.0 vs 22.1mo, p=0.004; 50-64yr: 14.6 vs 20.7mo, p=0.0001; >65yr 9.7 vs 14.5mo, p=0.002). When stratified by age and race, males had similar or superior survival compared to females in most subgroups, however Black males under 50yrs had markedly inferior OS compared with Black females (median OS 10.4mo vs 17.1mo for Black females, p=0.0083) and compared with White patients (Table). Conclusions: Young Black males with metastatic ccRCC demonstrate remarkably poor OS in this cohort; whereas males otherwise have a more favorable prognosis. Potential hypotheses to explain this disparity include differences in obesity and smoking incidence in this population as well as unmeasured factors impacting access to care.[Table: see text]
Collapse
Affiliation(s)
- Claud Grigg
- Levine Cancer Institute, Atrium Health, Charlotte, NC
| | | | | | - Peter E Clark
- Levine Cancer Institute, Atrium Health, Charlotte, NC
| | | | | | - Jason Zhu
- Levine Cancer Institute, Atrium Health, Charlotte, NC
| | | | | |
Collapse
|
11
|
Kadakia KC, Trufan SJ, Musselwhite LW, Wesson ZJ, Hwang JJ, Salem ME. Predictors of early mortality in early and late onset pancreatic cancer (PC). J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.4_suppl.543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
543 Background: The incidence of early-onset PC (EOPC) is rising and is associated with substantial mortality. We sought to identify independent predictors of early mortality in a cohort of EOPC and matched older patients (pts). Methods: Pts with EOPC (≤50 years) and matched cohorts of average (51-69, AOPC) and late (≥70, LOPC) onset PC by sex, race, year of diagnosis, and presence of metastatic disease were identified using the institutional tumor registry for years 2011-2018. Demographic and clinicopathologic characteristics were retrieved. Overall time of survival was assessed using Kaplan-Meier curves and the Cox Proportional Hazards modeling. Multivariable regression was conducted to evaluate for predictors of early mortality in non-metastatic and metastatic pts, defined as either death within six months of diagnosis compared to those surviving at least 12 months. Results: In total, 100 pts with EOPC (median age 47, range 29-50), 100 pts with AOPC (median age 60, range 51-69), and 100 pts with LOPC (median age 78, range 70-93) were analyzed. Of these, 46% were female, 28% were black, and 43% had metastatic disease at presentation. In non-metastatic pts, the 12-mo. survival rate by age group was: EOPC 74.4% (95% CI 59-85), AOPC 60% (95% CI 43-73), and LOPC 32.4% (95% CI 18-47). Variables associated with mortality within 6 months of diagnosis in non-metastatic pts on univariable analysis included age group, BMI ≤25, ECOG performance status (PS), neutrophil-to-lymphocyte ratio ≥5 (NLR5), CA 19-9 ≥130, no surgical resection, and no adjuvant chemotherapy. Multivariable regression confirmed no surgical resection (Odds Ratio [OR] 9.6, 95% CI 3-29), no receipt of chemotherapy (OR 6.9, 95% CI 2-21), and NLR5 (OR 5.4, 95% CI 1-22) as independent predictors for early mortality in non-metastatic pts. In metastatic pts, the 12-mo. survival rate by age group was: EOPC 32.6% (95% CI 19-47), AOPC 27% (95% CI 15-41), and LOPC 5.8% (95% CI 1-16). On univariable analysis, variables associated with mortality within 6 months of diagnosis included age group, ECOG PS, and NLR5. Multivariable regression confirmed LOPC (OR 11.6, 95% CI 2-61) and NLR5 (OR 11, 95% CI 2-54) as independent variables for early mortality. Race, sex, BMI, CA 19-9, smoking, alcohol use, primary tumor location, and site of metastases were not associated with early mortality in metastatic pts. No difference in independent predictors of early mortality between EOPC and older pts were identified. Conclusions: In this cohort of EOPC and matched older pts, LOPC (age ≥70) and NLR5 were independently associated with early mortality by 6 months in metastatic pts. In non-metastatic pts, lack of curative intent surgery, no receipt of chemotherapy, and NLR5 were independently associated with early mortality. There were no independent predictors for early mortality that distinguished EOPC and older pts. Further work is needed to identify prognostic factors unique to EOPC.
Collapse
|
12
|
Musselwhite LW, Trufan SJ, Kadakia KC, Hwang JJ, Salem ME. The prevalence of common KRAS variants and associated outcomes in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.4_suppl.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
173 Background: KRAS is the most common driver oncogene in mCRC. Comprehensive analysis of KRAS variants prevalence and the relationship between variants and outcomes are lacking. Herein, we aimed to examine the impact of KRAS variants on outcomes in patients (pts) with mCRC. Methods: A retrospective review of pts with mCRC with known KRAS mutation status was performed. Fisher’s exact test was used to analyze the association between KRAS variants. Cox Proportional Hazard modeling was used to study the relationship between KRAS variants and overall survival (OS). Kaplan-Meier method was used to assess OS. Results: A total of 423 pts diagnosed with mCRC from 2014-2020 with available extended KRAS status were evaluated. Median age at diagnosis was 59.8 yrs (22.3-92 range), 57% were male, 22% were Black, and 75% presented with de novo metastatic disease. A majority (56%) of tumors harbored KRAS mutations. The most frequent KRAS variants were G12D 47% (111), G12V 12% (28), G12C 13% (31), G13D 9% (21), and 20% (47) were other variants. In univariate analyses, the presence of a KRAS mutation, Black race, de novo metastatic disease, age, receipt of chemotherapy, and receipt of surgery were associated with OS. Tumor location was not associated with OS. In multivariable analyses, mutation type was a significant predictor of death and the presence of G12D was associated with an increased risk of death compared to G12V and KRAS wildtype. There was no increased risk of death in pairwise comparisons of G12D and G13D or other KRAS variants. Black race, de novo metastatic disease, and no receipt of surgery were additional independent predictors of death (Table). With a median follow-up of 25.7 months (mo.), median OS was 35.5 mo. (95% CI 10.5-50.9) with G12C, Not Reached (NR) (95% CI 21-NR) with G12V, 36.2 mo. (95%CI 14.9-58.5) with G13D, 26.2 mo. (95% CI 21.8-37) with G12D, 39.6 mo. (95% CI 22.4-47.9) for other KRAS mutations, and 59.6 mo. (95%CI 48.2-NA) for KRAS wildtype, respectively (p=0.0003). Conclusions: Our findings highlight differences in unadjusted overall survival when comparing G12D to some other KRAS variants. Codon and amino acid-specific mutations of KRAS should be considered when evaluating prognosis and further study on treatment effects and sequencing is warranted. [Table: see text]
Collapse
|
13
|
Squires MH, Ethun CG, Donahue EE, Benbow JH, Anderson CJ, Jagosky MH, Manandhar M, Patt JC, Kneisl JS, Salo JC, Hill JS, Ahrens W, Prabhu RS, Livingston MB, Gower NL, Needham M, Trufan SJ, Fields RC, Krasnick BA, Bedi M, Votanopoulos K, Chouliaras K, Grignol V, Roggin KK, Tseng J, Poultsides G, Tran TB, Cardona K, Howard JH. ASO Visual Abstract: Extremity Soft Tissue Sarcoma-A Multi-institutional Validation of Prognostic Nomograms. Ann Surg Oncol 2022. [PMID: 35088171 DOI: 10.1245/s10434-021-11263-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Affiliation(s)
| | | | - Erin E Donahue
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | | | - Colin J Anderson
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.,Musculoskeletal Institute, Atrium Health, Charlotte, NC, USA
| | | | | | - Joshua C Patt
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.,Musculoskeletal Institute, Atrium Health, Charlotte, NC, USA
| | - Jeffrey S Kneisl
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.,Musculoskeletal Institute, Atrium Health, Charlotte, NC, USA
| | | | - Joshua S Hill
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - William Ahrens
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | | | | | - Nicole L Gower
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | | | - Sally J Trufan
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Ryan C Fields
- Washington University School of Medicine, St. Louis, MO, USA
| | | | - Meena Bedi
- Medical College of Wisconsin, Milwaukee, WI, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Squires MH, Ethun CG, Donahue EE, Benbow JH, Anderson CJ, Jagosky MH, Manandhar M, Patt JC, Kneisl JS, Salo JC, Hill JS, Ahrens W, Prabhu RS, Livingston MB, Gower NL, Needham M, Trufan SJ, Fields RC, Krasnick BA, Bedi M, Votanopoulos K, Chouliaras K, Grignol V, Roggin KK, Tseng J, Poultsides G, Tran TB, Cardona K, Howard JH. Extremity Soft Tissue Sarcoma: A Multi-Institutional Validation of Prognostic Nomograms. Ann Surg Oncol 2022; 29:3291-3301. [PMID: 35015183 DOI: 10.1245/s10434-021-11205-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Accepted: 11/15/2021] [Indexed: 12/11/2022]
Abstract
BACKGROUND Prognostic nomograms for patients with resected extremity soft tissue sarcoma (STS) include the Sarculator and Memorial Sloan Kettering (MSKCC) nomograms. We sought to validate these two nomograms within a large, modern, multi-institutional cohort of resected primary extremity STS patients. METHODS Resected primary extremity STS patients from 2000 to 2017 were identified across nine high-volume U.S. institutions. Predicted 5- and 10-year overall survival (OS) and distant metastases cumulative incidence (DMCI), and 4-, 8-, and 12-year disease-specific survival (DSS) were calculated with Sarculator and MSKCC nomograms, respectively. Predicted survival probabilities stratified in quintiles were compared in calibration plots to observed survival assessed by Kaplan-Meier estimates. Cumulative incidence was estimated for DMCI. Harrell's concordance index (C-index) assessed discriminative ability of nomograms. RESULTS A total of 1326 patients underwent resection of primary extremity STS. Common histologies included: undifferentiated pleomorphic sarcoma (35%), fibrosarcoma (13%), and leiomyosarcoma (9%). Median tumor size was 8.0 cm (IQR 4.5-13.0). Tumor grade distribution was: Grade 1 (13%), Grade 2 (9%), Grade 3 (78%). Median OS was 172 months, with estimated 5- and 10-year OS of 70% and 58%. C-indices for 5- and 10-year OS (Sarculator) were 0.72 (95% CI 0.70-0.75) and 0.73 (95% CI 0.70-0.75), and 0.72 (95% CI 0.69-0.75) for 5- and 10-year DMCI. C-indices for 4-, 8-, and 12-year DSS (MSKCC) were 0.71 (95% CI 0.68-0.75). Calibration plots showed good prognostication across all outcomes. CONCLUSIONS Sarculator and MSKCC nomograms demonstrated good prognostic ability for survival and recurrence outcomes in a modern, multi-institutional validation cohort of resected primary extremity STS patients. External validation of these nomograms supports their ongoing incorporation into clinical practice.
Collapse
Affiliation(s)
| | | | - Erin E Donahue
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | | | - Colin J Anderson
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.,Musculoskeletal Institute, Atrium Health, Charlotte, NC, USA
| | | | | | - Joshua C Patt
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.,Musculoskeletal Institute, Atrium Health, Charlotte, NC, USA
| | - Jeffrey S Kneisl
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.,Musculoskeletal Institute, Atrium Health, Charlotte, NC, USA
| | | | - Joshua S Hill
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - William Ahrens
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | | | | | - Nicole L Gower
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | | | - Sally J Trufan
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Ryan C Fields
- Washington University School of Medicine, St. Louis, MO, USA
| | | | - Meena Bedi
- Medical College of Wisconsin, Milwaukee, WI, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Salem ME, Puccini A, Trufan SJ, Sha W, Kadakia KC, Hartley ML, Musselwhite LW, Symanowski JT, Hwang JJ, Raghavan D. Impact of Sociodemographic Disparities and Insurance Status on Survival of Patients with Early-Onset Colorectal Cancer. Oncologist 2021; 26:e1730-e1741. [PMID: 34288237 PMCID: PMC8488791 DOI: 10.1002/onco.13908] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2021] [Accepted: 07/13/2021] [Indexed: 12/12/2022] Open
Abstract
Background Low socioeconomic status (SES) has been linked to worse survival in patients with colorectal cancer (CRC); however, the impact of SES on early‐onset CRC remains undescribed. Materials and Methods Retrospective analysis of data from the National Cancer Database (NCDB) between 2004 and 2016 was conducted. We combined income and education to form a composite measure of SES. Logistic regression and χ2 testing were used to examine early‐onset CRC according to SES group. Survival rates and Cox proportional hazards models compared stage‐specific overall survival (OS) between the SES groups. Results In total, 30,903 patients with early‐onset CRC were identified, of whom 78.7% were White; 14.5% were Black. Low SES compared with high SES patients were more likely to be Black (26.3% vs. 6.1%) or Hispanic (25.3% vs. 10.5%), have T4 tumors (21.3% vs. 17.8%) and/or N2 disease (13% vs. 11.1%), and present with stage IV disease (32.8% vs. 27.7%) at diagnosis (p < .0001, all comparisons). OS gradually improved with increasing SES at all disease stages (p < .001). In stage IV, the 5‐year survival rate was 13.9% vs. 21.7% for patients with low compared with high SES. In multivariable analysis, SES (low vs. high group; adjusted hazard ratio [HRadj], 1.35; 95% confidence interval [CI], 1.26–1.46) was found to have a significant effect on survival (p < .0001) when all of the confounding variables were adjusted. Insurance (not private vs. private; HRadj, 1.38; 95% CI, 1.31–1.44) mediates 31% of the SES effect on survival. Conclusion Patients with early‐onset CRC with low SES had the worst outcomes. Our data suggest that SES should be considered when implementing programs to improve the early detection and treatment of patients with early‐onset CRC. Implications for Practice Low socioeconomic status (SES) has been linked to worse survival in patients with colorectal cancer (CRC); however, the impact of SES on early‐onset CRC remains undescribed. In this retrospective study of 30,903 patients with early‐onset CRC in the National Cancer Database, a steady increase in the yearly rate of stage IV diagnosis at presentation was observed. The risk of death increased as socioeconomic status decreased. Race and insurance status were independent predictors for survival. Implementation of programs to improve access to care and early diagnostic strategies among younger adults, especially those with low SES, is warranted. The incidence of and mortality from early‐onset colorectal cancer (CRC) is on the rise. This article details the relationship between socioeconomic status and clinical outcomes of young adults with early‐onset CRC.
Collapse
Affiliation(s)
- Mohamed E Salem
- Departments of Solid Tumor Oncology, Levine Cancer Institute, Charlotte, North Carolina, USA
| | - Alberto Puccini
- Ospedale Policlinico San Martino IRCCS, University of Genova, Genoa, Italy
| | - Sally J Trufan
- Cancer Biostatistics, Levine Cancer Institute, Charlotte, North Carolina, USA
| | - Wei Sha
- Cancer Biostatistics, Levine Cancer Institute, Charlotte, North Carolina, USA
| | - Kunal C Kadakia
- Departments of Solid Tumor Oncology, Levine Cancer Institute, Charlotte, North Carolina, USA
| | - Marion L Hartley
- The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA
| | - Laura W Musselwhite
- Departments of Solid Tumor Oncology, Levine Cancer Institute, Charlotte, North Carolina, USA
| | - James T Symanowski
- Cancer Biostatistics, Levine Cancer Institute, Charlotte, North Carolina, USA
| | - Jimmy J Hwang
- Departments of Solid Tumor Oncology, Levine Cancer Institute, Charlotte, North Carolina, USA
| | - Derek Raghavan
- Departments of Solid Tumor Oncology, Levine Cancer Institute, Charlotte, North Carolina, USA
| |
Collapse
|
16
|
Squires MH, Ethun CG, Donahue EE, Benbow JH, Anderson CJ, Jagosky MH, Salo JC, Hill JS, Ahrens W, Prabhu RS, Livingston MB, Gower NL, Needham M, Trufan SJ, Fields RC, Krasnick BA, Bedi M, Abbott DE, Schwartz P, Votanopoulos K, Chouliaras K, Grignol V, Roggin KK, Tseng J, Poultsides G, Tran TB, Cardona K, Howard JH. A multi-institutional validation study of prognostic nomograms for retroperitoneal sarcoma. J Surg Oncol 2021; 124:829-837. [PMID: 34254691 DOI: 10.1002/jso.26586] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Accepted: 06/12/2021] [Indexed: 12/30/2022]
Abstract
BACKGROUND AND OBJECTIVES Prognostic nomograms for patients undergoing resection of retroperitoneal sarcoma (RPS) include the Sarculator and Memorial Sloan Kettering (MSK) sarcoma nomograms. We sought to validate the Sarculator and MSK nomograms within a large, modern multi-institutional cohort of patients with primary RPS undergoing resection. METHODS Patients who underwent resection of primary RPS between 2000 and 2017 across nine high-volume US institutions were identified. Predicted 7-year disease-free (DFS) and overall survival (OS) and 4-, 8-, and 12-year disease-specific survival (DSS) were calculated from the Sarculator and MSK nomograms, respectively. Nomogram-predicted survival probabilities were stratified in quintiles and compared in calibration plots to observed survival outcomes assessed by Kaplan-Meier estimates. Discriminative ability of nomograms was quantified by Harrell's concordance index (C-index). RESULTS Five hundred and two patients underwent resection of primary RPS. Histologies included leiomyosarcoma (30%), dedifferentiated liposarcoma (23%), and well-differentiated liposarcoma (15%). Median tumor size was 14.0 cm (interquartile range [IQR], 8.5-21.0 cm). Tumor grade distribution was: Grade 1 (27%), Grade 2 (17%), and Grade 3 (56%). Median DFS was 31.5 months; 7-year DFS was 29%. Median OS was 93.8 months; 7-year OS was 51%. C-indices for 7-year DFS, and OS by the Sarculator nomogram were 0.65 (95% confidence interval [CI]: 0.62-0.69) and 0.69 (95%CI: 0.65-0.73); plots demonstrated good calibration for predicting 7-year outcomes. The C-index for 4-, 8-, and 12-year DSS by the MSK nomogram was 0.71 (95%CI: 0.67-0.75); plots demonstrated similarly good calibration ability. CONCLUSIONS In a diverse, modern validation cohort of patients with resected primary RPS, both Sarculator and MSK nomograms demonstrated good prognostic ability, supporting their ongoing adoption into clinical practice.
Collapse
Affiliation(s)
- Malcolm H Squires
- Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Cecilia G Ethun
- Division of Surgical Oncology, Emory University, Atlanta, Georgia, USA
| | - Erin E Donahue
- Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Jennifer H Benbow
- Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Colin J Anderson
- Department of Orthopedic Oncology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.,Musculoskeletal Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Megan H Jagosky
- Department of Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Jonathan C Salo
- Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Joshua S Hill
- Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - William Ahrens
- Department of Pathology, Atrium Health, Charlotte, North Carolina, USA
| | - Roshan S Prabhu
- Department of Radiation Oncology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Michael B Livingston
- Department of Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Nicole L Gower
- Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Mckenzie Needham
- Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Sally J Trufan
- Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
| | - Ryan C Fields
- Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Bradley A Krasnick
- Department of Surgery, School of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Meena Bedi
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
| | - Daniel E Abbott
- Department of Surgery, University of Wisconsin, Madison, Wisconsin, USA
| | - Patrick Schwartz
- Department of Surgery, University of Wisconsin, Madison, Wisconsin, USA
| | | | | | - Valerie Grignol
- Division of Surgical Oncology, The Ohio State University, Columbus, OH, USA
| | - Kevin K Roggin
- Department of Surgery, University of Chicago, Chicago, Illinois, USA
| | - Jennifer Tseng
- Department of Surgery, University of Chicago, Chicago, Illinois, USA
| | - George Poultsides
- Department of Surgery, Stanford University, Palo Alto, California, USA
| | - Thuy B Tran
- Department of Surgery, Stanford University, Palo Alto, California, USA
| | - Kenneth Cardona
- Division of Surgical Oncology, Emory University, Atlanta, Georgia, USA
| | | |
Collapse
|
17
|
Kadakia KC, Trufan SJ, Jagosky MH, Worrilow WM, Harrison BW, Broyhill KL, Hwang JJ, Musselwhite LW, Aktas A, Walsh D, Salem ME. Early-onset pancreatic cancer: an institutional series evaluating end-of-life care. Support Care Cancer 2020; 29:3613-3622. [PMID: 33170401 DOI: 10.1007/s00520-020-05876-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Accepted: 11/02/2020] [Indexed: 11/24/2022]
Abstract
PURPOSE Little is known about the use of palliative and hospice care and their impact on healthcare utilization near the end of life (EOL) in early-onset pancreatic cancer (EOPC). METHODS Patients with EOPC (≤ 50 years) were identified using the institutional tumor registry for years 2011-2018, and demographic, clinical, and rates of referral to palliative and hospice services were obtained retrospectively. Predictors of healthcare utilization, defined as use of ≥ 1 emergency department (ED) visit or hospitalization within 30 days of death, place of death (non-hospital vs. hospital), and time from last chemotherapy administration prior to death, were assessed using descriptive, univariable, and multivariable analyses including chi-square and logistic regression models. RESULTS A total of 112 patients with EOPC with a median age of 46 years (range, 29-50) were studied. Forty-four percent were female, 28% were Black, and 45% had metastatic disease. Fifty-seven percent received palliative care at a median of 7.8 weeks (range 0-265) following diagnosis. The median time between last chemotherapy and death was 7.9 weeks (range 0-102). Seventy-four percent used hospice services prior to death for a median of 15 days (range 0-241). Rate of healthcare utilization at the EOL was 74% in the overall population. Black race and late use of chemotherapy were independently associated with increase in ED visits/hospitalization and hospital place of death. CONCLUSIONS Although we observed early referrals to palliative care among patients with newly diagnosed EOPC, short duration of hospice enrollment and rates of healthcare utilization prior to death were substantial.
Collapse
Affiliation(s)
- Kunal C Kadakia
- Gastrointestinal Medical Oncology, Department of Solid Tumor Oncology, Levine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, NC, 28204, Charlotte, USA. .,Department of Supportive Oncology, Levine Cancer Institue, Atrium Health, NC, Charlotte, USA.
| | - Sally J Trufan
- Department of Cancer Biostatistics, Levine Cancer Institue, Atrium Health, NC, Charlotte, USA
| | - Megan H Jagosky
- Gastrointestinal Medical Oncology, Department of Solid Tumor Oncology, Levine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, NC, 28204, Charlotte, USA
| | - William M Worrilow
- Gastrointestinal Medical Oncology, Department of Solid Tumor Oncology, Levine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, NC, 28204, Charlotte, USA
| | - Bradley W Harrison
- Gastrointestinal Medical Oncology, Department of Solid Tumor Oncology, Levine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, NC, 28204, Charlotte, USA
| | - Katherine L Broyhill
- Department of Genetics, Levine Cancer Institue, Atrium Health, NC, Charlotte, USA
| | - Jimmy J Hwang
- Gastrointestinal Medical Oncology, Department of Solid Tumor Oncology, Levine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, NC, 28204, Charlotte, USA
| | - Laura W Musselwhite
- Gastrointestinal Medical Oncology, Department of Solid Tumor Oncology, Levine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, NC, 28204, Charlotte, USA
| | - Aynur Aktas
- Department of Supportive Oncology, Levine Cancer Institue, Atrium Health, NC, Charlotte, USA
| | - Declan Walsh
- Department of Supportive Oncology, Levine Cancer Institue, Atrium Health, NC, Charlotte, USA
| | - Mohamed E Salem
- Gastrointestinal Medical Oncology, Department of Solid Tumor Oncology, Levine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, NC, 28204, Charlotte, USA
| |
Collapse
|
18
|
Abstract
There has been increasing utilization of minimally invasive surgical approaches. This study evaluates the effect of surgical approach on total lymph node harvest in gastrectomy. Patients undergoing gastrectomy for gastric adenocarcinoma between 2007 and 2018 were reviewed retrospectively. Data collected included age, gender, race, BMI, neoadjuvant therapy, tumor stage, surgical approach, and total number of lymph nodes harvested. The total number of harvested lymph nodes for open, laparoscopic, and robotic gastrectomy was compared using the Kruskal-Wallis test for univariate analysis and a Poisson regression model for multivariable analysis. One hundred four patients were identified. Median node harvest for open, laparoscopic, and robotic approaches were 16, 17, and 36, respectively. Multivariable analysis controlling for gender, BMI, pathological T stage, and year of operation demonstrates that surgical approach is statistically significantly associated with lymph node harvest ( F = 83.4, P < 0.0001). In multivariable analysis, robotic approach was associated with greater lymph node harvest than both open ( P < 0.0001) and laparoscopic ( P < 0.0001) approaches, whereas laparoscopic approach was associated with greater lymph node harvest than open ( P < 0.0001) approach. These data demonstrate that for patients undergoing gastrectomy for gastric adenocarcinoma at our institution, robotic approach is associated with greater lymph node harvest than both laparoscopic and open approaches.
Collapse
Affiliation(s)
- Michael D. Watson
- Division of Surgical Oncology, Carolinas Medical Center, Levine Cancer Institute, Charlotte, North Carolina and
| | - Sally J. Trufan
- Department of Biostatistics, Carolinas Healthcare System, Levine Cancer Institute, Charlotte, North Carolina
| | - Nicole L. Gower
- Division of Surgical Oncology, Carolinas Medical Center, Levine Cancer Institute, Charlotte, North Carolina and
| | - Joshua S. Hill
- Division of Surgical Oncology, Carolinas Medical Center, Levine Cancer Institute, Charlotte, North Carolina and
| | - Jonathan C. Salo
- Division of Surgical Oncology, Carolinas Medical Center, Levine Cancer Institute, Charlotte, North Carolina and
| |
Collapse
|
19
|
Hudson L, Gower N, Lenarcic S, Trufan SJ, White RL. Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants. Ann Surg Oncol 2020; 27:2248-2254. [PMID: 31974710 DOI: 10.1245/s10434-019-08191-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Indexed: 11/18/2022]
Abstract
INTRODUCTION The National Comprehensive Cancer Network (NCCN) developed clinical practice guidelines for germline pathogenic variants in highly penetrant genes, such as TP53 and PTEN, and in moderately penetrant genes, such as CHEK2, ATM and PALB2. Whether the practice of radiographic surveillance of patients with pathogenic variants in genes other than BRCA1/2 complies with current NCCN guidelines remains unclear. METHODS Retrospective review of patients identified with pathogenic variants in genes other than BRCA1/2 from 2007 through 2017 to determine if radiographic surveillance was in accordance with NCCN guidelines for mammography and consideration of magnetic resonance imaging (MRI). Exclusions included variants of unknown significance, pathogenic variants not associated with an increased risk of breast cancer, and previous breast cancer diagnosis. RESULTS After exclusions, 35 patients with pathogenic variants in ATM, CDH1, CHEK2, NBN, PALB2, PTEN, and STK11 genes were reviewed to assess whether radiographic surveillance was in accordance with NCCN guidelines. Guidelines for those with variants in ATM, CHEK2 and NBN includes annual mammography with tomosynthesis and consideration of breast MRI at age 40, variants in CDH1 and PALB2 at age 30, variants in PTEN at age 30-35 or 5-10 years before the earliest family breast cancer, and variants in STK11 at age 25. Of these 35 patients, 11 (31%) received mammography only; 11 (31%) received mammography and MRI, and 13 (37%) received no radiographic surveillance. Two of the 35 (6%) patients who received radiographic surveillance were diagnosed with ductal carcinoma in situ or invasive breast cancer. CONCLUSION Thirty-one percent of patients with pathogenic variants in genes other than BRCA1/2 received both mammography and MRI. Thirty-seven percent of patients with these highly penetrant and moderately penetrant genes received no radiographic follow-up, clearly demonstrating an opportunity for improvement.
Collapse
Affiliation(s)
- Laura Hudson
- Division of Surgical Oncology, Department of Surgery, Carolinas Medical Center, Levine Cancer Institute, Charlotte, NC, USA
| | - Nicole Gower
- Division of Surgical Oncology, Department of Surgery, Carolinas Medical Center, Levine Cancer Institute, Charlotte, NC, USA
| | - Stacy Lenarcic
- Department of Genetics, Levine Cancer Institute, Charlotte, NC, USA
| | - Sally J Trufan
- Department of Cancer Biostatistics, Levine Cancer Institute, Charlotte, NC, USA
| | - Richard L White
- Division of Surgical Oncology, Department of Surgery, Carolinas Medical Center, Levine Cancer Institute, Charlotte, NC, USA.
| |
Collapse
|
20
|
Watson MD, Trufan SJ, Gower NL, Hill JS, Salo JC. Effect of Surgical Approach on Node Harvest in Robotic Gastrectomy. Am Surg 2019; 85:794-799. [PMID: 31560299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
There has been increasing utilization of minimally invasive surgical approaches. This study evaluates the effect of surgical approach on total lymph node harvest in gastrectomy. Patients undergoing gastrectomy for gastric adenocarcinoma between 2007 and 2018 were reviewed retrospectively. Data collected included age, gender, race, BMI, neoadjuvant therapy, tumor stage, surgical approach, and total number of lymph nodes harvested. The total number of harvested lymph nodes for open, laparoscopic, and robotic gastrectomy was compared using the Kruskal-Wallis test for univariate analysis and a Poisson regression model for multivariable analysis. One hundred four patients were identified. Median node harvest for open, laparoscopic, and robotic approaches were 16, 17, and 36, respectively. Multivariable analysis controlling for gender, BMI, pathological T stage, and year of operation demonstrates that surgical approach is statistically significantly associated with lymph node harvest (F = 83.4, P < 0.0001). In multivariable analysis, robotic approach was associated with greater lymph node harvest than both open (P < 0.0001) and laparoscopic (P < 0.0001) approaches, whereas laparoscopic approach was associated with greater lymph node harvest than open (P < 0.0001) approach. These data demonstrate that for patients undergoing gastrectomy for gastric adenocarcinoma at our institution, robotic approach is associated with greater lymph node harvest than both laparoscopic and open approaches.
Collapse
|
21
|
White RL, Palmer PP, Trufan SJ, Sarma D. Does Neoadjuvant Chemotherapy for Breast Cancer Affect Lymph Node Harvest Rates? Am Surg 2019. [DOI: 10.1177/000313481908500724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Some authors report that patients receiving neoadjuvant chemotherapy have fewer lymph nodes harvested during axillary dissection and more dissections with < 10 nodes compared with patients who undergo surgery initially. We sought to determine whether there was a difference between these patient groups in terms of number of nodes harvested and number of dissections with < 10 nodes. Retrospective review of 258 patients diagnosed with breast cancer who underwent an axillary lymph node dissection between July 1,2015, and December 31, 2017 was performed. Chi-squared test was used to assess differences between patient groups. Of 258 patients undergoing dissection, 48 per cent received neoadjuvant chemotherapy; 52 per cent underwent surgery as first therapeutic intervention. Mean number of nodes resected; 14.3 + 6.3 for patients with no prior chemotherapy versus 14.9 + 6.6 for patients with neoadjuvant chemotherapy ( P = 0.48). For patients undergoing surgery as first intervention, 21 per cent had < 10 nodes harvested. For patients receiving neo-adjuvant chemotherapy, 20 per cent had < 10 nodes harvested. Patients who received neoadjuvant chemotherapy showed no statistically significant difference in the number of lymph nodes harvested during axillary dissection compared with patients undergoing surgery as first intervention. Neoadjuvant chemotherapy does not reduce the node harvest at the time of axillary dissection.
Collapse
Affiliation(s)
- Richard L. White
- Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, and the
| | - Pooja P. Palmer
- Department of Cancer Biostatistics, Levine Cancer Institute, Charlotte, North Carolina
| | - Sally J. Trufan
- Department of Cancer Biostatistics, Levine Cancer Institute, Charlotte, North Carolina
| | - Deba Sarma
- Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, and the
| |
Collapse
|
22
|
White RL, Palmer PP, Trufan SJ, Sarma D. Does Neoadjuvant Chemotherapy for Breast Cancer Affect Lymph Node Harvest Rates? Am Surg 2019; 85:690-694. [PMID: 31405409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Some authors report that patients receiving neoadjuvant chemotherapy have fewer lymph nodes harvested during axillary dissection and more dissections with < 10 nodes compared with patients who undergo surgery initially. We sought to determine whether there was a difference between these patient groups in terms of number of nodes harvested and number of dissections with < 10 nodes. Retrospective review of 258 patients diagnosed with breast cancer who underwent an axillary lymph node dissection between July 1, 2015, and December 31, 2017 was performed. Chi-squared test was used to assess differences between patient groups. Of 258 patients undergoing dissection, 48 per cent received neoadjuvant chemotherapy; 52 per cent underwent surgery as first therapeutic intervention. Mean number of nodes resected; 14.3 + 6.3 for patients with no prior chemotherapy versus 14.9 + 6.6 for patients with neoadjuvant chemotherapy (P = 0.48). For patients undergoing surgery as first intervention, 21 per cent had < 10 nodes harvested. For patients receiving neoadjuvant chemotherapy, 20 per cent had < 10 nodes harvested. Patients who received neoadjuvant chemotherapy showed no statistically significant difference in the number of lymph nodes harvested during axillary dissection compared with patients undergoing surgery as first intervention. Neoadjuvant chemotherapy does not reduce the node harvest at the time of axillary dissection.
Collapse
|
23
|
Salo JC, Meadors PL, Trufan SJ, Gower NL, Watson MD, Jeck LA, Hill JS, Walsh D. Patient-reported distress and symptoms predict post-esophagectomy outcomes. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.e15567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15567 Background: Esophagectomy is accompanied by significant morbidity, mortality and altered quality of life. Understanding the factors responsible for adverse post-operative outcomes is essential for risk stratification in the selection of patients for surgery. Patient-reported measures are important not only as treatment outcome metrics, but also in predicting tolerance to therapy. Postoperative length of stay is a convenient measurement of patient tolerance of surgery. Our study aim was to determine whether preoperative patient-reported measures could add additional predictive power to clinical variables in predicting postoperative length of stay. Methods: A tablet-based symptom screening tool measured Distress, Anxiety (GAD-2), and cancer-related symptoms preoperatively. A generalized linear model predicting postoperative length of stay was constructed using age, gender, insurance status, income, T stage, and sarcopenia (hand-grip strength < 25kg). Patient-reported variables were then evaluated for their ability to predict length of stay in addition to these clinical factors. Factors found not significant (p > 0.05) are indicated N.S. Results: Esophagectomy (n = 58): Median age 62 (IQR 54-70) and 46 men (79%). Adenocarcinoma in 52 (90%). Neoadjuvant chemoradiation administered in 37 (64%). Major complications occurred in 13 (22%). Median postoperative length of stay was 8 days (IQR 6-10). Distress, Pain, Nausea/Vomiting, Trouble Swallowing, and Insurance or Financial Concerns independently predicted postoperative longer length of stay on multivariable analysis, while accounting for preoperative clinical factors. Conclusions: Preoperative cancer patient symptom reporting adds additional information to traditional clinical factors in predicting length of stay post-esophagectomy. Patient-reported measures may identify patients who benefit from interventions for preoperative optimization.[Table: see text]
Collapse
Affiliation(s)
- Jonathan C. Salo
- Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC
| | | | - Sally J Trufan
- Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC
| | - Nicole Lee Gower
- Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC
| | | | - Lauren A Jeck
- Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC
| | - Joshua S. Hill
- Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC
| | - Declan Walsh
- Levine Cancer Institute, Atrium Health, Charlotte, NC
| |
Collapse
|
24
|
Meadors PL, Trufan SJ, Walsh K, Walsh D. Patient reported outcomes and predictors of distress. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.6559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6559 Background: ASCO/NCCN guidelines recommend screening for multifactorial distress in cancer patients. Understanding predictors of cancer related distress can lead to early intervention and improve clinical outcomes, symptom management, and operational efficiency. Through electronic distress screening (EDS), patient reported outcomes (PRO) were collected across 42 practice locations. Methods: EDS has 39 questions related to cancer related distress including: distress, cancer symptoms/side effects, malnutrition, depression, anxiety, social/family support, financial, and spiritual concerns. 27,106 patients completed screens between 2017-2018. Multivariate analysis and logistic regressions determined predictors of distress for completed screens overall, registry matched, and within 60 days of diagnosis. Results: Median age was 59 (IQR 18-101) and 65% were female. Five symptoms consistently predicted clinically significant distress ≥ 4: anxiety, fatigue, pain, poor emotional coping, and sleep. Diagnosis (dx), staging at time of dx, and timing of screen did not independently predict distress. Factors predicting clinically significant distress varied across geographic regions. Conclusions: In large patient population, five key PROs are predictive of clinically significant distress and could potentially impact clinical outcomes. Early PROs predictive of distress were consistent along the continuum, thus the importance of early symptom identification. EDS can help custom tailor supportive oncology programs to mitigate symptoms related to cancer distress. [Table: see text]
Collapse
Affiliation(s)
| | - Sally J Trufan
- Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC
| | | | - Declan Walsh
- Harry R. Horvitz Center for Palliative Medicine, Cleveland, OH
| |
Collapse
|
25
|
Burgess EF, Livasy C, Trufan SJ, Hartman A, Guerrieri R, Naso C, Clark PE, Grigg C, Symanowski JT, Raghavan D. Impact of Aurora kinase A and B expression on response to neoadjuvant chemotherapy and patient outcome in muscle-invasive bladder cancer (MIBC). J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.7_suppl.393] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
393 Background: Identification of robust biomarkers that predict likelihood of benefit from neoadjuvant chemotherapy (NAC) in patients with MIBC remains an unmet need. Previous studies have implicated tumor overexpression of aurora kinases A (AURKA) and B (AURKB) as a mechanism of chemo-resistance. Because overexpression of AURKA has also emerged as a potential biomarker for detection of high-risk urothelial carcinoma, we sought to characterize the expression of AURKA, AURKB with clinical outcomes in MIBC patients who received NAC and to test the hypothesis that tumor overexpression of AURKA and AURKB would predict for residual MIBC. Methods: 47 patients with MIBC who received NAC prior to cystectomy were retrospectively identified. Immunohistochemistry for AURKA and AURKB was performed on pre-treatment diagnostic transurethral resection of bladder tumors and matched cystectomy specimens. Logistic regression models were estimated to determine the impact of pre-NAC expression on pathologic staging at cystectomy. Receiver Operator Characteristic curves (ROC) were calculated to assess diagnostic predictive ability of AURKA and AURKB. AURKA and AURKB were assessed for association with relapse-free survival (RFS) and overall survival (OS) using Kaplan-Meier techniques and Cox proportional hazards models. Results: 22 of 47 [46.8%] patients had residual muscle-invasive (ypT2-4) urothelial carcinoma after NAC. Neither baseline tumor expression of AURKA (ROC = 0.54, p = 0.71) nor AURKB (ROC = 0.46, p = 0.98) predicted for ypT2-4 status. However, baseline expression of AURKA above the 75th percentile for this cohort, determined by the percentage of tumor cells positive, was associated with an inferior RFS, [HR = 3.79, [1.40, 10.26] p = 0.005] and OS, [HR = 5.84, [2.14, 15.98], p < 0.001]. Similar trends for worse survival outcomes were also observed for high AURKB levels. Conclusions: Although baseline tumor AURKA and AURKB expression did not predict for pathologic residual MIBC after NAC, high expression of AURKA and AURKB predicted for inferior RFS and OS. Further evaluation of AURKA and AURKB as potential biomarkers and therapeutic targets in MIBC is warranted.
Collapse
Affiliation(s)
| | - Chad Livasy
- Levine Cancer Institute, Atrium Health, Charlotte, NC
| | | | - Aaron Hartman
- Levine Cancer Institute, Atrium Health, Charlotte, NC
| | | | - Caroline Naso
- Levine Cancer Institute, Atrium Health, Charlotte, NC
| | - Peter E Clark
- Levine Cancer Institute, Atrium Health, Charlotte, NC
| | - Claud Grigg
- Levine Cancer Institute, Atrium Health, Charlotte, NC
| | | | | |
Collapse
|
26
|
Lorimer PD, Motz BM, Watson M, Trufan SJ, Prabhu RS, Hill JS, Salo JC. Enteral Feeding Access Has an Impact on Outcomes for Patients with Esophageal Cancer Undergoing Esophagectomy: An Analysis of SEER-Medicare. Ann Surg Oncol 2019; 26:1311-1319. [PMID: 30783851 DOI: 10.1245/s10434-019-07230-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Indexed: 01/09/2023]
Abstract
BACKGROUND Optimal nutrition after esophagectomy is challenging due to alterations in eating, both from the tumor and during surgical recovery. Enteral nutrition via feeding tube is commonly used. The impact of feeding tubes on post-esophagectomy outcomes was examined in a large national data set. METHODS Patients with esophageal cancer (1998-2013) undergoing esophagectomy were extracted from the Surveillance Epidemiology and End Results-Medicare database. Chi-square and t tests were used to compare categorical and continuous variables. Time trend analyses were performed with Cochran-Armitage survival using log-rank and multivariable analysis with generalized linear modeling. RESULTS The study examined 2495 patients. The majority had enteral feeding access (71%, n = 1794) during the perioperative period. Mortality among the patients with feeding tubes was lower at 30 days (5.4% vs 8.4%), 60 days (9.0% vs 13.0%), and 90 days (12.2% vs 15.8%). In the multivariable analysis, the patients with feeding tubes had improved short-term survival at 30 days (odds ratio [OR], 0.65, 95% confidence interval [CI], 0.46-0.93), 60 days (OR, 0.64; 95% CI, 0.49-0.85), and 90 days (OR, 0.70; 95% CI, 0.54-0.90). The hospital stay was shorter for the patients undergoing enteral feeding tube placement (17.9 vs 19.5 days; p = 0.04). Discharge destination (home vs health care facility) showed no difference. CONCLUSIONS Feeding tubes in patients undergoing esophagectomy were associated with an increase in short-term survival up to 90 days after surgery. Feeding tube placement was not associated with higher rates of non-home discharges and did not prolong the hospital stay.
Collapse
Affiliation(s)
- Patrick D Lorimer
- Division of Surgical Oncology, Department of Surgery, Carolinas Medical Center, Levine Cancer Institute, Charlotte, NC, USA
| | - Benjamin M Motz
- Division of Surgical Oncology, Department of Surgery, Carolinas Medical Center, Levine Cancer Institute, Charlotte, NC, USA
| | - Michael Watson
- Division of Surgical Oncology, Department of Surgery, Carolinas Medical Center, Levine Cancer Institute, Charlotte, NC, USA
| | - Sally J Trufan
- Department of Biostatistics, Carolinas Medical Center, Levine Cancer Institute, Charlotte, NC, USA
| | | | - Joshua S Hill
- Division of Surgical Oncology, Department of Surgery, Carolinas Medical Center, Levine Cancer Institute, Charlotte, NC, USA
| | - Jonathan C Salo
- Division of Surgical Oncology, Department of Surgery, Carolinas Medical Center, Levine Cancer Institute, Charlotte, NC, USA.
| |
Collapse
|
27
|
Watson MD, Trufan SJ, Gower NL, Hill JS, Salo JC. Effect of surgical approach on node harvest in gastrectomy: Analysis of the National Cancer Database. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.4_suppl.47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
47 Background: Recent studies demonstrate significant surgical outcome advantages for patients undergoing minimally invasive versus open gastrectomy. Lymph node harvest at the time of gastrectomy is an indicator of adequate surgical resection and greater harvest is associated with improved staging and patient outcomes. Our aim is to evaluate lymph node harvest based on surgical approach. Our hypothesis is that a minimally invasive approach, particularly robot-assisted, will be associated with higher lymph node harvest. Methods: Patients undergoing gastrectomy for gastric adenocarcinoma in the period of 2010-2015 were identified using the National Cancer Database (NCDB). Data collected includes demographic data, institutional volume, approach, type of gastrectomy, tumor size, tumor location, pathologic T classification, year of diagnosis, Charlson-Deyo score and node harvest. Outcomes for patients undergoing open, laparoscopic, and robot-assisted gastrectomy were compared with univariate analysis and with a multivariate generalized linear mixed model (GLMM). Results: 19,555 patients were identified. There were 12,400 men (63.4%) and the mean age was 66.3 ± 12.5 years. 13,486 (69.0%) patients underwent open gastrectomy, 5,023 (25.7%) laparoscopic gastrectomy, and 1,046 (5.3%) robotic-assisted gastrectomy. Mean node harvest for open was 16.1 ± 11.5, laparoscopic was 15.1 ± 12.1, and robotic-assisted was 17.2 ± 13.3. Using a GLMM which controlled for the above listed covariates, robotic-assisted gastrectomy was associated with higher node harvest than both open (p = 0.041) and laparoscopic (p < 0.001) while open was associated with higher node harvest than laparoscopic (p < 0.001). There were 1582 operations with zero nodes harvested. In a sub-analysis of resections where at least one node was harvested (n = 17,973), the mean node harvest for open was 16.9 ± 11.1, laparoscopic was 17.5 ± 11.2, and robotic was 19.7 ± 12.3. Conclusions: This data suggests that a robot-assisted approach is associated with increased node harvest compared to laparoscopic and open approach in gastrectomy.
Collapse
Affiliation(s)
| | | | - Nicole Lee Gower
- Carolinas Medical Center, Levine Cancer Institute, Charlotte, NC
| | - Joshua S. Hill
- Carolinas Medical Center, Levine Cancer Institute, Charlotte, NC
| | - Jonathan C. Salo
- Carolinas Medical Center, Levine Cancer Institute, Charlotte, NC
| |
Collapse
|
28
|
Messinger CJ, Gurzau ES, Breitschwerdt EB, Tomuleasa CI, Trufan SJ, Flonta MM, Maggi RG, Berindan-Neagoe I, Rabinowitz PM. Seroprevalence of Bartonella species, Coxiella burnetii and Toxoplasma gondii among patients with hematological malignancies: A pilot study in Romania. Zoonoses Public Health 2017; 64:485-490. [PMID: 28328183 DOI: 10.1111/zph.12353] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2016] [Indexed: 12/27/2022]
Abstract
Patients receiving immunosuppressive cancer treatments in settings where there is a high degree of human-animal interaction may be at increased risk for opportunistic zoonotic infections or reactivation of latent infections. We sought to determine the seroprevalence of selected zoonotic pathogens among patients diagnosed with haematologic malignancies and undergoing chemotherapeutic treatments in Romania, where much of the general population lives and/or works in contact with livestock. A convenience sample of 51 patients with haematologic cancer undergoing chemotherapy at a referral clinic in Cluj-Napoca, Romania, was surveyed regarding animal exposures. Blood samples were obtained and tested for evidence of infection with Bartonella species, Coxiella burnetii and Toxoplasma gondii, which are important opportunistic zoonotic agents in immunocompromised individuals. 58.8% of participants reported living or working on a farm, and living or working on a farm was associated with contact with livestock and other animals. 37.5% of participants were IgG seroreactive against one or more of five Bartonella antigens, and seroreactivity was statistically associated with living on farms. Farm dwellers were 3.6 times more likely to test IgG seroreactive to Bartonella antibodies than non-farm dwellers. 47.1% of the participants tested T. gondii IgG positive and 13.7% tested C. burnetii IgG positive, indicating past or latent infection. C. burnetii IgM antibodies were detected in four participants (7.8%), indicating possible recent infection. These results indicate that a large proportion of patients with haematologic cancer in Romania may be at risk for zoonotic infections or for reactivation of latent zoonotic infections, particularly with respect to Bartonella species. Special attention should be paid to cancer patients' exposure to livestock and companion animals in areas where much of the population lives in rural settings.
Collapse
Affiliation(s)
| | - E S Gurzau
- Environmental Health Center, Cluj-Napoca, Romania.,Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - E B Breitschwerdt
- Intracellular Pathogens Research Laboratory, Center for Comparative Medicine and Translational Research, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA.,Galaxy Diagnostics, Research Triangle Park, NC, USA
| | - C I Tomuleasa
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.,Department of Hematology, Oncology Institute Ion Chiricuta, Cluj-Napoca, Romania
| | - S J Trufan
- Center for One Health Research, Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA
| | - M M Flonta
- Microbiology Laboratory, Infectious Diseases Hospital, Cluj-Napoca, Romania
| | - R G Maggi
- Intracellular Pathogens Research Laboratory, Center for Comparative Medicine and Translational Research, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA.,Galaxy Diagnostics, Research Triangle Park, NC, USA
| | - I Berindan-Neagoe
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.,Department of Experimental Pathology, Oncology Institute Ion Chiricuta, Cluj-Napoca, Romania.,Department of Experimental Therapeutics, M.D. Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - P M Rabinowitz
- Center for One Health Research, Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA
| |
Collapse
|
29
|
Slizovskiy IB, Conti LA, Trufan SJ, Reif JS, Lamers VT, Stowe MH, Dziura J, Rabinowitz PM. Reported health conditions in animals residing near natural gas wells in southwestern Pennsylvania. J Environ Sci Health A Tox Hazard Subst Environ Eng 2015; 50:473-81. [PMID: 25734823 DOI: 10.1080/10934529.2015.992666] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Natural gas extraction activities, including the use of horizontal drilling and hydraulic fracturing, may pose potential health risks to both human and animal populations in close proximity to sites of extraction activity. Because animals may have increased exposure to contaminated water and air as well as increased susceptibility to contaminant exposures compared to nearby humans, animal disease events in communities living near natural gas extraction may provide "sentinel" information useful for human health risk assessment. Community health evaluations as well as health impact assessments (HIAs) of natural gas exploration should therefore consider the inclusion of animal health metrics in their assessment process. We report on a community environmental health survey conducted in an area of active natural gas drilling, which included the collection of health data on 2452 companion and backyard animals residing in 157 randomly-selected households of Washington County, Pennsylvania (USA). There were a total of 127 reported health conditions, most commonly among dogs. When reports from all animals were considered, there were no significant associations between reported health condition and household proximity to natural gas wells. When dogs were analyzed separately, we found an elevated risk of 'any' reported health condition in households less than 1km from the nearest gas well (OR = 3.2, 95% CI 1.07-9.7), with dermal conditions being the most common of canine disorders. While these results should be considered hypothesis generating and preliminary, they suggest value in ongoing assessments of pet dogs as well as other animals to better elucidate the health impacts of natural gas extraction on nearby communities.
Collapse
Affiliation(s)
- I B Slizovskiy
- a Section of Comparative Medicine , Yale University School of Medicine , New Haven , Connecticut , USA
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Rabinowitz PM, Slizovskiy IB, Lamers V, Trufan SJ, Holford TR, Dziura JD, Peduzzi PN, Kane MJ, Reif JS, Weiss TR, Stowe MH. Proximity to natural gas wells and reported health status: results of a household survey in Washington County, Pennsylvania. Environ Health Perspect 2015; 123:21-6. [PMID: 25204871 PMCID: PMC4286272 DOI: 10.1289/ehp.1307732] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/17/2013] [Accepted: 08/20/2014] [Indexed: 05/04/2023]
Abstract
BACKGROUND Little is known about the environmental and public health impact of unconventional natural gas extraction activities, including hydraulic fracturing, that occur near residential areas. OBJECTIVES Our aim was to assess the relationship between household proximity to natural gas wells and reported health symptoms. METHODS We conducted a hypothesis-generating health symptom survey of 492 persons in 180 randomly selected households with ground-fed wells in an area of active natural gas drilling. Gas well proximity for each household was compared with the prevalence and frequency of reported dermal, respiratory, gastrointestinal, cardiovascular, and neurological symptoms. RESULTS The number of reported health symptoms per person was higher among residents living < 1 km (mean ± SD, 3.27 ± 3.72) compared with > 2 km from the nearest gas well (mean ± SD, 1.60 ± 2.14; p = 0.0002). In a model that adjusted for age, sex, household education, smoking, awareness of environmental risk, work type, and animals in house, reported skin conditions were more common in households < 1 km compared with > 2 km from the nearest gas well (odds ratio = 4.1; 95% CI: 1.4, 12.3; p = 0.01). Upper respiratory symptoms were also more frequently reported in persons living in households < 1 km from gas wells (39%) compared with households 1-2 km or > 2 km from the nearest well (31 and 18%, respectively) (p = 0.004). No equivalent correlation was found between well proximity and other reported groups of respiratory, neurological, cardiovascular, or gastrointestinal conditions. CONCLUSION Although these results should be viewed as hypothesis generating, and the population studied was limited to households with a ground-fed water supply, proximity of natural gas wells may be associated with the prevalence of health symptoms including dermal and respiratory conditions in residents living near natural gas extraction activities. Further study of these associations, including the role of specific air and water exposures, is warranted.
Collapse
Affiliation(s)
- Peter M Rabinowitz
- Yale University School of Medicine, Yale University, New Haven, Connecticut, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
OBJECTIVE Family accommodation of patients with obsessive-compulsive disorder, i.e., participation in symptoms and modification of personal and family routines, was assessed in relation to family stress, functioning, and attitudes toward the patient. METHOD Primary caretakers for 34 patients with obsessive-compulsive disorder were interviewed to assess the nature and frequency of accommodating behaviors. The caretakers also completed several measures of family functioning. RESULTS Of the 34 spouses or parents, 30 (88.2%) reported accommodating the patient. Family accommodation correlated with poor family functioning, rejecting attitudes toward the patient, and several types of family stress. CONCLUSIONS Family accommodation of patients with obsessive-compulsive disorder was associated with global family dysfunction and stress. This study suggests that families' efforts to accommodate patients may be intended to reduce patient anxiety or anger directed at relatives.
Collapse
Affiliation(s)
- L Calvocoressi
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT
| | | | | | | | | | | | | |
Collapse
|
32
|
Calvocoressi L, McDougle CI, Wasylink S, Goodman WK, Trufan SJ, Price LH. Inpatient treatment of patients with severe obsessive-compulsive disorder. Hosp Community Psychiatry 1993; 44:1150-4. [PMID: 8132187 DOI: 10.1176/ps.44.12.1150] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Patients with obsessive-compulsive disorder may experience severely disabling symptoms and require hospitalization. Based on treatment of 77 such patients admitted to a long-term general psychiatric research unit over a seven-year period, the authors present pharmacologic, psychosocial, and behavioral management strategies for treating these patients on general psychiatric units. The treatment guidelines require only modest modifications of standard practice and can be adapted for use on general units without specialized staff training. Some patients with obsessive-compulsive disorder exhibit strong control and dependency needs and disrupt the milieu in characteristic ways. These patients may generate conflict among staff about whether the patients can control obsessive-compulsive behaviors; they may anger other patients because of the large amount of staff attention they demand. Educating staff about obsessive-compulsive patients' control and dependency needs and enlisting the support of fellow patients can improve the milieu.
Collapse
Affiliation(s)
- L Calvocoressi
- Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven
| | | | | | | | | | | |
Collapse
|